Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuki Iwayanagi

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Pharmaceutical Research|December 15, 2007
HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1Yuki Iwayanagi, Tappei Takada, Hiroshi Suzuki
Pharmaceutical Research|December 21, 2006
LXR alpha transactivates mouse organic solute transporter alpha and beta via IR-1 elements shared with FXRMasae Okuwaki, Tappei Takada, Yuki Iwayanagi, et al.
Pharmaceutical Research|October 19, 2010
Human NPC1L1 expression is positively regulated by PPARαYuki Iwayanagi, Tappei Takada, Fumiya Tomura, et al.
Drug Metabolism and Pharmacokinetics|March 6, 2016
PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding modelKenta Haraya, Tatsuhiko Tachibana, Yuki Iwayanagi, et al.
Mabs|April 8, 2017
Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibodyAtsuhiko Maeda, Yuki Iwayanagi, Kenta Haraya, et al.
Mabs|September 11, 2018
MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicityNobuo Sekiguchi, Chiyomi Kubo, Ayako Takahashi, et al.
Plos One|May 14, 2013
Engineered monoclonal antibody with novel antigen-sweeping activity in vivoTomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 31, 2015
Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc EngineeringYuki Iwayanagi, Tomoyuki Igawa, Atsuhiko Maeda, et al.
Experimental Dermatology|October 8, 2016
Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibodySohei Oyama, Hidetomo Kitamura, Taichi Kuramochi, et al.
Scientific Reports|April 26, 2017
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseasesTaku Fukuzawa, Zenjiro Sampei, Kenta Haraya, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Pharmaceutical Research|December 15, 2007
HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1Yuki Iwayanagi, Tappei Takada, Hiroshi Suzuki
Pharmaceutical Research|December 21, 2006
LXR alpha transactivates mouse organic solute transporter alpha and beta via IR-1 elements shared with FXRMasae Okuwaki, Tappei Takada, Yuki Iwayanagi, et al.
Pharmaceutical Research|October 19, 2010
Human NPC1L1 expression is positively regulated by PPARαYuki Iwayanagi, Tappei Takada, Fumiya Tomura, et al.
Drug Metabolism and Pharmacokinetics|March 6, 2016
PK/PD analysis of a novel pH-dependent antigen-binding antibody using a dynamic antibody-antigen binding modelKenta Haraya, Tatsuhiko Tachibana, Yuki Iwayanagi, et al.
Mabs|April 8, 2017
Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibodyAtsuhiko Maeda, Yuki Iwayanagi, Kenta Haraya, et al.
Mabs|September 11, 2018
MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicityNobuo Sekiguchi, Chiyomi Kubo, Ayako Takahashi, et al.
Plos One|May 14, 2013
Engineered monoclonal antibody with novel antigen-sweeping activity in vivoTomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 31, 2015
Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc EngineeringYuki Iwayanagi, Tomoyuki Igawa, Atsuhiko Maeda, et al.
Experimental Dermatology|October 8, 2016
Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibodySohei Oyama, Hidetomo Kitamura, Taichi Kuramochi, et al.
Scientific Reports|April 26, 2017
Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseasesTaku Fukuzawa, Zenjiro Sampei, Kenta Haraya, et al.
Pageof 1